2022 World Conference on Lung Cancer (ePosters)-EP14.04-002. The Impact of Response on Survival in Extensive-Stage Small-Cell Lung Cancer in the CASPIAN Study

Pdf Summary

The objective of this study was to examine the relationship between patients' response status at a specific timepoint and their subsequent overall survival (OS) and progression-free survival (PFS) outcomes in patients with extensive-stage small cell lung cancer (ES-SCLC) treated with durvalumab plus chemotherapy (DEP) or chemotherapy alone (EP) in the CASPIAN study. The study found that response status at 12 weeks was associated with longer OS and PFS in both treatment arms, with responders treated with DEP having longer OS and PFS compared to responders treated with EP. Furthermore, responders treated with DEP had a significantly lower likelihood of experiencing an OS or PFS event during follow-up compared to those treated with EP. Sensitivity analyses using alternative landmark timepoints at 6 weeks and 20 weeks yielded consistent results.<br /><br />The study highlights that response status at a specific timepoint can serve as an indicator of long-term survival for patients with ES-SCLC, especially those receiving DEP. This information could potentially be useful in making survival predictions earlier in the treatment pathway of ES-SCLC patients. The CASPIAN study previously demonstrated that DEP improved OS and PFS compared to EP alone, making it the first approved immunotherapy-containing regimen to achieve these benefits in 1L treatment of patients with ES-SCLC.<br /><br />The study analyzed survival outcomes conditional on response status at the landmark timepoint using various statistical models and found significant associations between response and longer OS and PFS. A multivariate analysis showed that response at 12 weeks and the interaction between treatment and response were significant predictors of longer OS and PFS. The study also conducted sensitivity analyses at 6 weeks and 20 weeks, which yielded similar results.<br /><br />The findings of this study provide valuable insights into the relationship between response status and long-term survival outcomes in ES-SCLC patients treated with DEP or EP. These findings could have important implications for clinical practice, helping clinicians make informed treatment decisions and predict survival outcomes based on response status at the landmark timepoint. However, the study acknowledges certain limitations, such as the use of clinical trial-based response categories and the need for further research to assess OS and PFS based on real-world clinical practice assessments of response.

Asset Subtitle

Sukhvinder Johal

Meta Tag

Speaker Sukhvinder Johal

Topic Small Cell Lung Cancer and Neuro-endocrine Tumours - RW

Keywords

response status

overall survival

progression-free survival

extensive-stage small cell lung cancer

durvalumab plus chemotherapy

CASPIAN study

longer OS

longer PFS

treatment arms

clinical practice